Regen Biopharma Faces Financial Challenges Amidst Stable Revenues and Rising Operational Losses

Company Overview: Regen Biopharma, Inc. (OTCBB: RGBP) is focused on the development of regenerative medical applications, primarily through licensing agreements.

Latest Developments:

• Revenues for Q2 2025 were stable, showing minor fluctuations compared to the same period in 2024, with total revenues at $59,065.
• Operating expenses saw an increase due to consulting and professional fees, totaling $172,414 for the quarter, up from $160,135 in 2024.
• A significant derivative income of $128,963 was recognized, contrasting previous periods of loss.

Income Statement Highlights:

• Net Revenue:
  • Q2 2025: $59,065
  • Q2 2024: $59,064
• Loss from Operations:
  • Q2 2025: $(113,349)
  • Q2 2024: $(101,071)
• Net Loss:
  • Q2 2025: $(19,354)
  • Q2 2024: $(122,454)
• Net Loss for Six Months:
  • 2025: $(534,739)
  • 2024: $(267,387)

Balance Sheet Insights:

• Total Assets: $169,482 as of March 31, 2025, compared to $161,084 as of September 30, 2024.
• Total Liabilities: $5,867,880 as of March 31, 2025, increasing from $5,378,456.
• Stockholders’ Equity (Deficit): $(5,698,399)

Other Notable Points:

• Decrease in cash position to $1,761 as of March 31, 2025, down from $78,114 in 2024.
• The company is dependent on obtaining additional working capital funding to continue operations.
• There is a substantial doubt about the company’s ability to continue as a going concern.

Conclusion: Regen Biopharma, Inc. is navigating financial challenges, with dwindling cash resources and increasing debt. While revenue has stabilized, the company continues to accumulate significant operational losses, necessitating immediate fundraising efforts.